Automation of tissue homogenization in protein analysis workflows using the Omni LH96 automated workstation

Accurately quantifying proteins in biospecimens through tissue homogenization is critical to studies that positively impact our understanding of human health and disease. Within staple techniques, LC-MS has become a powerful analytical method that provides insights into project milestones, not limited to drug efficacy, mechanisms of action, target engagement, and safety. From mRNA and lipid nanoparticles (LNPs) to gene therapy (GTx) and protein degraders (PROTAC), LC-MS is making an impact across drug modalities and their discovery platforms.

Tissues, whether for protein or other analytes investigation, are immensely valuable biospecimens that touch the success of multiple streams in disease research, where variability in sample handling and analyte preparation are core laboratory challenges. Many labs are turning to automated tissue rotor-stators, rapid homogenizers and grinders to accelerate their tissue homogenization workflows. In this application note, valuable data is shared from Pfizer’s on-site evaluation and adoption of the Omni automated homogenizer:

• Benchmark and efficiency testing on several tissue types
• Comparison data to semi-automated bead milling
• Increase in sample size/weight processing range
• Reduction in overall processing time, hands-on analyst time, and ease of knowledge transfer/technology training

Rather than relying on multiple homogenizers to scale their throughput capacity, labs can rely on multi-sample homogenization using automation to maximize lab efficiencies. It also goes without saying that one homogenizer is easier for scheduling use as well as maintenance compared to multiple lower throughput homogenizers.

For research use only. Not for use in diagnostic procedures.